![Kazunori Yoshikawa](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Kazunori Yoshikawa
Director Ejecutivo en Veneno Technologies Co. Ltd. .
Cargos activos de Kazunori Yoshikawa
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Veneno Technologies Co. Ltd.
![]() Veneno Technologies Co. Ltd. BiotechnologyHealth Technology Veneno Technologies Co. Ltd. is a Japanese company that researches and develops therapeutic disulfide-rich peptides. The company is based in Tsukuba, Japan. The company was founded in 2020. The CEO is Kazunori Yoshikawa. | Director Ejecutivo | - | - |
Presidente | - | - |
Historial de carrera de Kazunori Yoshikawa
Antiguos cargos conocidos de Kazunori Yoshikawa.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
BONAC Corp.
![]() BONAC Corp. Medical SpecialtiesHealth Technology BONAC Corp. develops diagnostic drugs based on nucleic acid chemistry. The company was founded in February 2010 and is headquartered in Kurume, Japan. | Director/Miembro de la Junta | - | - |
AQUA Therapeutics Co., Ltd.
![]() AQUA Therapeutics Co., Ltd. Pharmaceuticals: MajorHealth Technology AQUA Therapeutics Co., Ltd. develops therapeutic drugs focused on the treatment of ophthalmological diseases. It uses a nucleic acid interference platform aimed at gene targets of select diseases. The firm's technologies include diabetic retinopathy, Periostin, and Bonac nucleic acid. It also offers research, development, manufacture, and marketing of other pharmaceuticals; non-medicinal products and cosmetics; and medical devices, instruments, and equipment. The firm also conducts medical research and consulting services. The company was founded by Kazunori Yoshikawa on March 19, 2012 and is headquartered in Kobe, Japan. | Director/Miembro de la Junta | 19/03/2012 | - |
Fundador | 19/03/2012 | - | |
Presidente | 19/03/2012 | - | |
CHUGAI PHARMACEUTICAL CO., LTD | Corporate Officer/Principal | - | - |
M's Science Corp.
![]() M's Science Corp. Miscellaneous Commercial ServicesCommercial Services M's Science Corp. engages in the research and development of drugs for the treatment of central nervous system (CNS) disorders and ocular diseases. It develops Cutamesine, an orally active compound that enhances neuroregeneration and facilitates the recovery of damaged CNS tissues from stress or ischemia-induced insults. The firm also develops therapeutic drugs for oncology. The company was founded by Shiro Mita in November 2000 and is headquartered in Kobe, Japan. | Director Administrativo | 31/03/2009 | - |
Comptroller/Controller/Auditor | 31/03/2009 | 31/03/2009 | |
Director/Miembro de la Junta | 31/03/2009 | - |
Formación de Kazunori Yoshikawa.
Tohoku University | Undergraduate Degree |
Estadísticas
Internacional
Japón | 7 |
Operativa
Director/Board Member | 3 |
President | 2 |
Chief Administrative Officer | 1 |
Sectorial
Health Technology | 5 |
Commercial Services | 2 |
Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
CHUGAI PHARMACEUTICAL CO., LTD | Health Technology |
Empresas privadas | 4 |
---|---|
M's Science Corp.
![]() M's Science Corp. Miscellaneous Commercial ServicesCommercial Services M's Science Corp. engages in the research and development of drugs for the treatment of central nervous system (CNS) disorders and ocular diseases. It develops Cutamesine, an orally active compound that enhances neuroregeneration and facilitates the recovery of damaged CNS tissues from stress or ischemia-induced insults. The firm also develops therapeutic drugs for oncology. The company was founded by Shiro Mita in November 2000 and is headquartered in Kobe, Japan. | Commercial Services |
AQUA Therapeutics Co., Ltd.
![]() AQUA Therapeutics Co., Ltd. Pharmaceuticals: MajorHealth Technology AQUA Therapeutics Co., Ltd. develops therapeutic drugs focused on the treatment of ophthalmological diseases. It uses a nucleic acid interference platform aimed at gene targets of select diseases. The firm's technologies include diabetic retinopathy, Periostin, and Bonac nucleic acid. It also offers research, development, manufacture, and marketing of other pharmaceuticals; non-medicinal products and cosmetics; and medical devices, instruments, and equipment. The firm also conducts medical research and consulting services. The company was founded by Kazunori Yoshikawa on March 19, 2012 and is headquartered in Kobe, Japan. | Health Technology |
BONAC Corp.
![]() BONAC Corp. Medical SpecialtiesHealth Technology BONAC Corp. develops diagnostic drugs based on nucleic acid chemistry. The company was founded in February 2010 and is headquartered in Kurume, Japan. | Health Technology |
Veneno Technologies Co. Ltd.
![]() Veneno Technologies Co. Ltd. BiotechnologyHealth Technology Veneno Technologies Co. Ltd. is a Japanese company that researches and develops therapeutic disulfide-rich peptides. The company is based in Tsukuba, Japan. The company was founded in 2020. The CEO is Kazunori Yoshikawa. | Health Technology |
- Bolsa de valores
- Insiders
- Kazunori Yoshikawa
- Experiencia